Serum protein profile of Crohn's disease treated with infliximab

Journal of Crohn's and Colitis

Volumn 7, Issue 10, 2013, Pages

  Gazouli, Maria ^a,b   Anagnostopoulos, Athanasios K ^c   Papadopoulou, Aggeliki ^c   Vaiopoulou, Anna ^a,b   Papamichael, Konstantinos ^d   Mantzaris, Gerassimos ^d   Theodoropoulos, George E ^e   Anagnou, Nicholas P ^a,b   Tsangaris, George Th ^c  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^b Academy of Athens Biomedical Research Foundation   (Greece)

^c BIOMEDICAL RESEARCH FOUNDATION   (Greece)

^d EVANGELISMOS HOSPITAL   (Greece)

^e HIPPOKRATION HOSPITAL   (Greece)

Author keywords

Crohn's disease; Inflammatory bowel disease; Infliximab; Proteomics

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA2 GLYCOPROTEIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN E; AZATHIOPRINE; BETA2 GLYCOPROTEIN 1; C REACTIVE PROTEIN; CLUSTERIN; COMPLEMENT COMPONENT C1R; COMPLEMENT COMPONENT C4; GLYCOPROTEIN; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; PLASMINOGEN; PREDNISOLONE; TRANSFERRIN; VITAMIN D BINDING PROTEIN;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; COLON; CONTROLLED STUDY; CROHN DISEASE; FEMALE; GEL ELECTROPHORESIS; HUMAN; ILEUM; IMMUNOBLOTTING; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEOMICS; REMISSION; TREATMENT RESPONSE; UPREGULATION;

CROHN'S DISEASE; INFLAMMATORY BOWEL DISEASE; INFLIXIMAB; PROTEOMICS;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; APOLIPOPROTEIN A-I; APOLIPOPROTEINS E; BETA 2-GLYCOPROTEIN I; BIOLOGICAL MARKERS; CLUSTERIN; COMPLEMENT C1R; COMPLEMENT C4B; CROHN DISEASE; FEMALE; GLYCOPROTEINS; HUMANS; IMMUNOGLOBULINS; MALE; MIDDLE AGED; PLASMINOGEN; PROTEOMICS; REMISSION INDUCTION; TRANSFERRIN; UP-REGULATION; VITAMIN D-BINDING PROTEIN; YOUNG ADULT;

EID: 84884166743     PISSN: 18739946     EISSN: 18764479     Source Type: Journal    
DOI: 10.1016/j.crohns.2013.02.021     Document Type: Article

References (40)

1. Podolsky D.K. Inflammatory bowel disease. N Engl J Med 2002, 347:417-429.
2. Lapaquette P., Brest P., Hofman P., et al. Etiology of Crohn's disease: many roads lead to autophagy. Mol Med (Berl) 2012, 90:987-996. [Epub ahead of print].
3. Cho J.H. The genetics and immunopathogenesis of inflammatory bowel disease. Nat Rev Immunol 2008, 8:458-466.
4. Budarf M.L., Labbé C., David G., et al. GWA studies: rewriting the story of IBD. Trends Genet 2009, 25:137-146.
5. Papamichael K., Gazouli M., Karakoidas C., et al. Association of TNF and FcγRIIIA gene polymorphisms with differential response to infliximab in a Greek cohort of Crohn's disease patients. Ann Gastroenterol 2011, 24:35-40.
6. Louis E., Vermeire S., Rutgeerts P., et al. A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism. Scand J Gastroenterol 2002, 37:818-824.
7. Pierik M., Vermeire S., Steen K.V., et al. Tumour necrosis factor-alpha receptor 1 and 2 polymorphisms in inflammatory bowel disease and their association with response to infliximab. Aliment Pharmacol Ther 2004, 20:303-310.
8. Cravatt B.F., Simon G.M., Yates J.R. The biological impact of mass-spectrometry-based proteomics. Nature 2007, 450:991-1000.
9. Hanash S.M., Pitteri S.J., Faca V.M. Mining the plasma proteome for cancer biomarkers. Nature 2008, 452:571-579.
10. Vaiopoulou A., Gazouli M., Theodoropoulos G., et al. Current advantages in the application of proteomics in inflammatory bowel disease. Dig Dis Sci 2012, 57:2755-2764.
11. Alex P., Gucek M., Li X. Applications of proteomics in the study of inflammatory bowel diseases: current status and future directions with available technologies. Inflamm Bowel Dis 2009, 15:616-629.
12. Meuwis M.A., Fillet M., Geurts P., et al. Biomarker discovery for inflammatory bowel disease, using proteomic serum profiling. Biochem Pharmacol 2007, 73:1422-1433.
13. Nanni P., Parisi D., Roda G., et al. Serum protein profiling in patients with inflammatory bowel diseases using selective solid-phase bulk extraction, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry and chemometric data analysis. Rapid Commun Mass Spectrom 2007, 21:4142-4148.
14. Danese S., Colombel J.F., Reinisch W., et al. Review article: infliximab for Crohn's disease treatment-shifting therapeutic strategies after 10years of clinical experience. Aliment Pharmacol Ther 2011, 33:857-869.
15. Yanai H., Hanauer S.B. Assessing response and loss of response to biological therapies in IBD. Am J Gastroenterol 2011, 106:685-698.
16. Chowers Y., Sturm A., Sans M., et al. Report of the ECCO workshop on anti-TNF therapy failures in inflammatory bowel diseases: biological roles and effects of TNF and TNF antagonists. J Crohns Colitis 2010, 4:367-376.
17. Allez M., Karmiris K., Louis E., et al. Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. J Crohns Colitis 2010, 4:355-366.
18. Danese S., Fiorino G., Reinisch W. Review article: causative factors and the clinical management of patients with Crohn's disease who lose response to anti-TNF-α therapy. Aliment Pharmacol Ther 2011, 34:1-10.
19. Meuwis M.A., Fillet M., Lutteri L., et al. Proteomics for prediction and characterization of response to infliximab in Crohn's disease: a pilot study. Clin Biochem 2008, 41:960-967.
20. Kolialexi A., Anagnostopoulos A.K., Papantoniou N., et al. Potential biomarkers for Turner in maternal plasma: possibility for noninvasive prenatal diagnosis. J Proteome Res 2010, 9:5164-5170.
21. Anagnostopoulos A.K., Kolialexi A., Mavrou A., et al. Proteomic analysis of amniotic fluid in pregnancies with Klinefelter syndrome foetuses. J Proteomics 2010, 73:943-950.
22. Hochberg B.Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B 1995, 57:289-300.
23. Dwivedi R.C., Dhindsa N., Krokhin O.V., et al. The effects of infliximab therapy on the serum proteome of rheumatoid arthritis patients. Arthritis Res Ther 2009, 11:R32.
24. Trocmé C., Marotte H., Baillet A., et al. Apolipoprotein A-I and platelet factor 4 are biomarkers for infliximab response in rheumatoid arthritis. Ann Rheum Dis 2009, 68:1328-1333.
25. Takeuchi T., Nakanishi T., Tabushi Y., et al. Serum protein profile of rheumatoid arthritis treated with anti-TNF therapy (infliximab). J Chromatogr B Analyt Technol Biomed Life Sci 2007, 855:66-70.
26. Hyka N., Dayer J.M., Modoux C., et al. Apolipoprotein A-I inhibits the production of interleukin-1beta and tumor necrosis factor-alpha by blocking contact-mediated activation of monocytes by T lymphocytes. Blood 2001, 97:2381-2389.
27. Dobmeyer J.M., Rexin M., Dobmeyer T.S., et al. Quantitation of apolipoprotein epsilon gene expression by competitive polymerase chain reaction in a patient with familial apolipoprotein E deficiency. Clin Chim Acta 1998, 274:119-137.
28. Wong M., Ziring D., Korin Y., et al. TNFalpha blockade in human diseases: mechanisms and future directions. Clin Immunol 2008, 126:121-136.
29. Papadakis K.A., Targan S.R. Role of cytokines in the pathogenesis of inflammatory bowel disease. Annu Rev Med 2000, 51:289-298.
30. Scallon B.J., Moore M.A., Trinh H., et al. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 1995, 7:251-259.
31. Gelissen I.C., Hochgrebe T., Wilson M.R., et al. Apolipoprotein J (clusterin) induces cholesterol export from macrophage-foam cells: a potential anti-atherogenic function?. Biochem J 1998, 331:231-237.
32. Agirbasli M., Inanc N., Baykan O.A., et al. The effects of TNF alpha inhibition on plasma fibrinolytic balance in patients with chronic inflammatory rheumatical disorders. Clin Exp Rheumatol 2006, 24:580-583.
33. Lloyd-Still J.D., Tomasi L. Neurovascular and thromboembolic complications of inflammatory bowel disease in childhood. J Pediatr Gastroenterol Nutr 1989, 9:461-466.
34. Ingegnoli F., Fantini F., Griffini S., et al. Anti-tumor necrosis factor alpha therapy normalizes fibrinolysis impairment in patients with active rheumatoid arthritis. Clin Exp Rheumatol 2010, 28:254-257.
35. Fischer R., Trudgian D.C., Wright C., et al. Discovery of candidate serum proteomic and metabolomic biomarkers in ankylosing spondylitis. Mol Cell Proteomics 2012, 11. [M111.013904].
36. Low J.M., Chauhan A.K., Gibson D.S., et al. Proteomic analysis of circulating immune complexes in juvenile idiopathic arthritis reveals disease-associated proteins. Proteomics Clin Appl 2009, 3:829-840.
37. Serada S., Fujimoto M., Ogata A., et al. iTRAQ-based proteomic identification of leucine-rich alpha-2 glycoprotein as a novel inflammatory biomarker in autoimmune diseases. Ann Rheum Dis 2010, 69:770-774.
38. Stoop M.P., Singh V., Dekker L.J., et al. Proteomics comparison of cerebrospinal fluid of relapsing remitting and primary progressive multiple sclerosis. PLoS One 2010, 5:e12442.
39. Stio M., Treves C., Martinesi M., et al. Effect of anti-TNF therapy and vitamin D derivatives on the proliferation of peripheral blood mononuclear cells in Crohn's disease. Dig Dis Sci 2004, 49:328-335.
40. Jensen L.J., Kuhn M., Stark M., et al. STRING 8-a global view on proteins and their functional interactions in 630 organisms. Nucleic Acids Res 2009, 37:D412-D416. [Database issue].